U.S. Consumer Durables Stock News

Institutional buying puts ACV Auctions (ACVA) back in focus Iridian Asset Management’s recent purchase of more than 1.1 million ACV Auctions (ACVA) shares, now its largest holding at nearly 9% of assets, has drawn fresh attention to the stock. The investment comes alongside record revenue figures, higher marketplace vehicle volumes, and improving adjusted EBITDA. This has prompted investors to reassess how the company’s current share price lines up with its business performance. See our...

In recent days, CDW has come under pressure after multiple Wall Street firms downgraded or maintained cautious ratings, citing concerns about weaker hardware spending and higher memory costs following revenue and guidance that fell short of expectations despite an earnings per share beat. At the same time, CDW is highlighting its capabilities in enterprise AI and cloud services through Mission Cloud’s work with AWS, underscoring the company’s push into higher-value technology solutions even...

Earlier this year, Monster Energy announced a partnership with Casey’s General Stores to launch a limited-time Ultra Red, White and Blue Razz drink, initially exclusive to Casey’s and CEFCO locations before a wider U.S. rollout. An important aspect of the launch is a joint US$200,000 donation to military-focused nonprofits, aligning the co-branded product with Casey’s community support efforts and visibility among service members through Monster’s Military Channels. We’ll now examine how...

Iridian’s increased stake and recent operating performance Hilton Grand Vacations (HGV) came into focus after Iridian Asset Management lifted its holdings by 190,909 shares in the fourth quarter, an US$8.11 million addition tied to recent operating trends. Iridian now allocates nearly 8% of its reportable assets to Hilton Grand Vacations, following company updates that included a 17% year over year rise in contract sales and reaffirmed full year adjusted EBITDA guidance. See our latest...

In recent weeks, Oric Pharmaceuticals has drawn increased attention as investors focused on its cancer resistance therapy pipeline, including Phase 1b candidates ORIC-114 and ORIC-944, and its collaborations with Pfizer, Bayer, and Johnson & Johnson. An interesting development is how this combination of early-stage assets and partnerships with large pharmaceutical companies is reshaping perceptions of Oric’s potential role in oncology drug development. Next, we’ll examine how this growing...

In January 2026, Dana Incorporated issued earnings guidance for 2025, projecting annual sales in the range of $7.30 billion to $7.70 billion. This new guidance gives investors a clearer view of Dana’s revenue expectations for the year, sharpening how its future prospects are assessed. Next, we’ll examine how Dana’s specified 2025 sales range shapes its investment narrative and what it could mean for forward expectations. The end of cancer? These 29 emerging AI stocks are developing tech that...

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...

National HealthCare Corporation recently reached a record high level after reporting 22.67% revenue growth over the past year and declaring a US$0.64 quarterly dividend per share, underscoring its focus on returning cash to shareholders. The company’s ‘GREAT’ financial health score, combined with strong recent results and ongoing dividend payments, may be reinforcing investor confidence in its operational resilience. We’ll now examine how National HealthCare’s robust revenue growth and...

In recent months, analysts have become more positive on The RealReal after the company reported past third-quarter results that outpaced forecasts for revenue and adjusted EBITDA. Alongside this, The RealReal’s introduction of its Athena AI system to support authentication, descriptions, and pricing underscores a push toward greater efficiency in its luxury resale operations. Next, we’ll explore how this combination of analyst confidence and Athena-driven operational enhancement shapes The...

In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score of 0.2 that places the diagnostics group in the distress zone. Alongside these concerns, the company has highlighted its role in blood-supply resilience and plans to report fourth-quarter and full-year 2025 results on February 11, 2026, underscoring a contrast between operational initiatives and...

PTC Therapeutics (PTCT) recently issued full year 2026 product revenue guidance of US$700 million to US$800 million, excluding Evrysdi royalties and collaboration revenue. This guidance serves as a key reference point for investors tracking the stock. See our latest analysis for PTC Therapeutics. The 12.18% 3 month share price return and 62.0% 1 year total shareholder return suggest momentum has been building around PTC Therapeutics, with the new 2026 product revenue guidance adding to recent...

Donnelley Financial Solutions recently reported Q3 2025 results that surpassed earnings expectations and outlined plans to increase the share of revenue from software solutions to 60% by 2028, while attracting new investment from the RAM Smid Composite fund. This pivot toward higher-margin software and technology-enabled compliance tools marks a meaningful shift in how the company positions itself within the regulatory and financial reporting ecosystem. We will now examine how Donnelley...

Recent analyst coverage highlighted Perdoceo Education’s past-year revenue growth of 24.23% and earnings-per-share growth of 22.33%, alongside strong profitability, minimal debt, and ample liquidity. Commentary also pointed to the company’s valuation as relatively attractive compared with industry peers, suggesting investors may see a balance of growth potential and financial resilience. Next, we’ll examine how this combination of robust earnings momentum and an apparently attractive...

Royalty Pharma, which acquires rights to portions of biopharmaceutical sales instead of conducting its own research, recently raised its dividend to US$0.235 payable in March 2026 and issued higher guidance ahead of its fourth quarter and full-year 2025 results scheduled for February 11, 2026. This comes after two years of flat sales and a 4.4 percentage point drop in adjusted operating margin over five years, highlighting the tension between investor optimism and questions about how the...

In its latest quarter, Worthington Enterprises reported US$327 million in revenue, surpassing market expectations but missing margin targets due to one-time items following its prior steel business separation. The results marked the company’s eighth consecutive quarter of clean reporting post-separation, a period during which analysts have maintained generally positive views on its prospects. Next, we’ll examine how stronger-than-expected revenue but softer, one-time-affected margins shapes...

In January 2026, Vornado Realty Trust, Hudson Pacific Properties and Blackstone Real Estate announced that Paramount Television Studios signed the first lease at Sunset Pier 94 Studios, Manhattan’s first purpose-built studio facility, ahead of its opening. This early 70,000-square-foot lease, supported by expanded New York State tax credits and strong tenant interest, underscores the project’s potential to generate long-term production-related income and community benefits, including new...

Element Solutions recently reported Q3 2025 earnings that came in ahead of forecasts and completed its acquisition of EFC Gases & Advanced Materials, bolstering its position in specialty chemicals for advanced technologies. This combination of stronger-than-expected results and an expanded footprint in semiconductor-related materials has reinforced investor attention on the company’s role in high-performance electronics manufacturing. Next, we’ll examine how Element Solutions’ EFC Gases &...

In recent months, XPEL reported Q3 2025 results with revenue surpassing forecasts but an earnings per share miss, while outlining plans to invest between US$75,000,000 and US$150,000,000 in capital expenditures over the next two years. This combination of stronger-than-expected revenue and sizable planned investment, alongside an outlook for margin expansion, has sharpened attention on how XPEL is positioning its business. Next, we will examine how XPEL’s sizable capital expenditure plan...

National Storage Affiliates Trust recently reported solid Q3 2025 results, with improved same-store revenue growth across most key markets and core FFO per share exceeding consensus expectations, while also preparing to release its Q4 2025 results in late February 2026. The company introduced a preferred equity investment program aimed at funding self-storage deals and deepening partnerships with former PRO operators, which management highlighted alongside its positive commentary on...

Why ICU Medical (ICUI) Is Back on Investors’ Radar ICU Medical (ICUI) is drawing fresh attention after recent commentary pointed to slower revenue growth than healthcare peers and an estimated 7.7% sales decline over the next 12 months, suggesting a tougher demand backdrop. See our latest analysis for ICU Medical. ICU Medical’s share price has pulled back 3.7% over the last day and 2.2% over the week, yet it still carries a 24.2% 3 month share price return and a weaker 1 year total...

Why the latest guidance and analyst sentiment matter Butterfly Network (BFLY) has drawn fresh attention after guiding for at least 17% year over year revenue growth in the fourth quarter of 2025, with several brokerage firms reiterating positive views on the stock. For you as an investor, that combination of explicit growth guidance and supportive analyst commentary creates a clear focal point: how much confidence you place in Butterfly’s ability to translate handheld ultrasound adoption into...

In recent days, New Fortress Energy has gained attention after outlining new partnerships, a South American expansion via a Brazilian deal, and progress on its LNG technology, while still contending with operational losses, high debt, and regulatory hurdles. An interesting angle for investors is how these growth-focused partnerships and technology advances are emerging alongside persistent questions about the company’s long-term financial resilience. We’ll now examine how the South American...

Why Xenon Pharmaceuticals is on investors’ radar today Xenon Pharmaceuticals (XENE) has been drawing fresh attention after recent share price swings. The stock closed at US$41.76 and has shown mixed returns over the past week, month, and past 3 months. See our latest analysis for Xenon Pharmaceuticals. While the recent 1-day share price return of 1.14% decline and 30-day share price return of 6.87% decline point to some cooling momentum, the 1-year total shareholder return of 4.53% and 5-year...

Brink's (BCO) is back in focus after reporting 16% growth in ATM managed services and digital retail solutions, the fastest North American growth in nine quarters, and raising full-year revenue and EBITDA guidance. See our latest analysis for Brink's. Those AMS and digital gains come after a multi month share price recovery, with Brink's posting an 8.37% 90 day share price return and a 35.82% 1 year total shareholder return. This suggests that momentum has been building rather than fading. If...